NCT03534180 2023-10-19
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
City of Hope Medical Center
Phase 2 Completed
Clinical Trials
9 trialsNCT00104884 2023-06-28
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00426764 2020-02-11
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Phase 2 Completed
NCT00765102 2019-11-25
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Celgene
Phase 2 Terminated
NCT00106418 2019-11-18
A Research Study for Patients With Prostate Cancer
Celgene
Phase 2 Completed
NCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT00085527 2013-09-05
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
University of Chicago
Phase 2 Withdrawn
NCT00087295 2012-11-02
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
SWOG Cancer Research Network
Phase 2 Terminated
NCT00299351 2006-03-06
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
Royal Marsden NHS Foundation Trust
Phase 2 Unknown